OCA 983

Drug Profile

OCA 983

Latest Information Update: 22 Mar 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Antibacterials; Beta-lactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 22 Mar 2002 Discontinued - Preclinical for Bacterial infections in USA (PO)
  • 12 Jan 2000 New profile
  • 12 Jan 2000 Preclinical development for Bacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top